Novocure Gains 37% on Pancreatic Cancer Device Clearance; Soleus Boosts Celcuity Stake
Novocure shares jumped 37% after FDA granted clearance for its Tumor Treating Fields device in pancreatic cancer, marking its first approval in this indication. Separately, Soleus Capital Management acquired 629,398 Celcuity shares valued at $180.36 million, boosting its stake to 6.7% of fund assets.
1. FDA Clearance Drives Novocure Stock Surge
On February 13, FDA approval of Novocure’s Tumor Treating Fields device for pancreatic cancer triggered a 37% share price jump. This marks the company’s first approval in this indication and could open a new multi-hundred-million-dollar revenue stream upon commercial launch later in 2026.
2. Soleus Capital’s Significant Celcuity Share Purchase
Also on February 13, Soleus Capital Management purchased 629,398 Celcuity shares, raising its holdings to over 1.8 million shares valued at $180.36 million. This stake now represents 6.7% of the fund’s assets under management and follows Celcuity’s 745% stock rally over the past year.